Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program

Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ...